Burning Rock Biotech Limited: FY2022 Form 20-F Summary
Business context and reporting period
This filing is an annual report for the fiscal year ended December 31, 2022, not a standalone quarterly filing. Burning Rock is a Cayman Islands holding company whose China operations are conducted primarily through a variable interest entity and its subsidiaries under contractual arrangements. The company develops and provides next-generation sequencing cancer therapy-selection tests, in-hospital laboratory solutions, pharma research and development services, minimal residual disease testing, and early cancer detection products. The consolidated financial statements are prepared under U.S. GAAP and reported in RMB.
Key financial metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | RMB563.2 million (US$81.7 million) | RMB507.9 million | +10.9% |
| Gross profit | RMB380.0 million (US$55.1 million) | RMB364.1 million | +4.4% |
| Gross margin | 67.5% | 71.7% | Down 4.2 percentage points |
| Operating loss | RMB980.4 million (US$142.1 million) | RMB797.1 million | Loss increased |
| Net loss | RMB971.2 million (US$140.8 million) | RMB796.7 million | +21.9% loss |
| Net loss per ordinary share | RMB9.35 (US$1.36) | RMB7.65 | Loss increased |
| Operating cash flow | Used RMB456.8 million (US$66.2 million) | Used RMB477.9 million | Cash burn modestly lower |
| Capital expenditures | RMB70.5 million (US$10.2 million) | RMB206.9 million | Lower investment spending |
| Cash and cash equivalents | RMB905.5 million (US$131.3 million) | RMB1.431 billion | Down 36.7% |
| Restricted cash | RMB19.8 million (US$2.9 million) | RMB7.8 million | Increased |
| Total liabilities | RMB429.1 million (US$62.2 million) | RMB433.3 million | Slightly lower |
| Shareholders’ equity | RMB1.158 billion (US$167.9 million) | RMB1.845 billion | Down 37.2% |
Operating expenses rose to RMB1.360 billion from RMB1.161 billion. Research and development expense increased 14.7% to RMB421.9 million, selling and marketing expense increased 22.2% to RMB370.3 million, and general and administrative expense increased 15.9% to RMB568.3 million. Share-based compensation was RMB326.8 million, compared with RMB282.4 million in 2021.
Revenue mix and operating performance
- Central laboratory revenue declined 1.4% to RMB314.8 million, representing 55.9% of total revenue. Patients tested declined to 27,353 from 28,199.
- In-hospital revenue increased 6.2% to RMB175.3 million, representing 31.1% of total revenue. Contracted partner hospitals increased from 41 to 49, while total partner hospitals reached 77 across 37 cities.
- Pharma research and development services revenue increased 212.8% to RMB73.2 million, or 13.0% of total revenue, driven by increased testing and companion-diagnostics development services.
- Central laboratory gross margin declined to 73.9% from 74.6%; in-hospital gross margin declined to 63.9% from 69.5%, primarily due to depreciation, new laboratory costs and inventory write-downs. Pharma services gross margin increased to 48.4% from 47.4%.
- The company launched its brPROPHET minimal residual disease product in March 2022. Its OverC multi-cancer early detection product received FDA Breakthrough Device Designation in January 2023, after the reporting period.
Material changes versus the prior comparable period
- Revenue growth continued but slowed from 18.1% in 2021 to 10.9% in 2022, while the net loss widened by 21.9%.
- Revenue mix shifted away from central laboratory testing toward pharma services and in-hospital products.
- COVID-19 restrictions materially affected operations in the second quarter, particularly in Shanghai. Activity resumed in the third and fourth quarters as restrictions eased, but patient testing for the full year remained below 2021 levels.
- Cash and cash equivalents declined by approximately RMB525.9 million, reflecting operating cash burn, capital spending and the RMB71.8 million share repurchase. The company repurchased 3,023,138 ADS-representing shares at an average price of US$2.83 per ADS under a completed US$10 million program.
- The company had no long-term borrowings as of December 31, 2022; the RMB2.4 million short-term borrowing outstanding at December 31, 2021 was repaid in July 2022.
- Management updated estimates for unused monitoring-package tests, recognizing approximately RMB12.0 million of additional revenue and reducing deferred revenue. Total breakage revenue recognized in 2022 was RMB26.4 million.
- Allowance for credit losses increased, including contract-asset allowances, and accrued liabilities included RMB39.0 million related to guaranteed returns for eligible employees under modified share-incentive arrangements.
Liquidity, outlook, risks and unusual items
Management stated that cash and cash equivalents, together with expected financing sources and operating resources, should meet current and anticipated general corporate needs for at least the next 12 months. However, the company continues to generate substantial operating losses and negative operating cash flow and may need additional equity or debt financing. Future equity financing could dilute shareholders, while debt financing could impose additional restrictions.
Operating lease obligations totaled RMB53.4 million, including RMB39.6 million due within one year and RMB13.8 million due in one to three years. The filing states that the company had no other significant capital commitments, long-term obligations or guarantees as of December 31, 2022.
- China regulatory, cybersecurity, data privacy and human genetic resources rules are evolving and could restrict operations, clinical studies, data use or overseas financing.
- The company relies on a VIE structure because foreign investment is restricted in businesses involving genomic diagnosis and treatment technology. Investors own the Cayman Islands holding company, not direct equity in the VIE. The contractual arrangements have not been tested in a PRC court and could be challenged or become unenforceable.
- Cash is concentrated in China and primarily denominated in RMB. Foreign-exchange controls and PRC restrictions on dividends, loans and cross-border transfers could limit the company’s ability to move funds to the holding company or pay investors.
- Market adoption, regulatory approvals, clinical validation and commercialization of MRD and early detection products remain uncertain. The filing provides no formal revenue, profitability or cash-flow guidance.
- The company identified product liability, professional liability, cybersecurity, intellectual property, supplier concentration, competition, COVID-19 and dependence on hospitals and physicians as material risks. It does not carry product liability or professional liability insurance.
- The PCAOB vacated its prior determination regarding inspection access in mainland China and Hong Kong in December 2022. The company therefore did not expect to be identified as a Commission-Identified Issuer after filing this report, but future inspection access remains a risk under the HFCA Act.
- Management and Ernst & Young Hua Ming LLP concluded that internal control over financial reporting was effective as of December 31, 2022. The auditors issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether the company can reduce operating losses and cash burn as revenue expands, particularly given the 2022 gross-margin decline.
- The sustainability and collectability of pharma services revenue and the expected timing of revenue from remaining performance obligations.
- The effect of monitoring-package breakage estimates and other revenue-recognition judgments on reported revenue.
- The status and renewal of NCCL, CLIA, CAP, medical-device and other regulatory certifications, including the NGS laboratory certification that was due for renewal in 2023.
- Whether brPROPHET and OverC achieve clinical validation, regulatory approval, reimbursement or broad commercial adoption.
- The enforceability and continuing regulatory acceptability of the VIE arrangements and the company’s ability to transfer cash from China.
- The scale of future equity issuance, share-based compensation and potential dilution; 20.1 million options were outstanding at December 31, 2022, and unrecognized share-based compensation was RMB491.6 million.
- Whether cash resources remain sufficient without additional financing, given continued losses, negative operating cash flow and the absence of dividends.